Intervention News

SAN FRANCISCO — New 1-year data show a novel system for transcatheter aortic valve replacement was safe and effective for adults with symptomatic severe aortic regurgitation at high surgical risk, a speaker reported at TCT 2023.

An integrated carotid artery stent system was associated with the lowest 1-year event rates in any well-powered, multicenter carotid revascularization trial, according to data presented at VIVA.23.

SAN FRANCISCO — In a new meta-analysis, researchers reaffirmed safety and efficacy of ticagrelor monotherapy to reduce major bleeding after 3-month dual antiplatelet therapy among patients who underwent PCI for ACS.

A novel bioabsorbable scaffold for tibial vessels was safe and associated with a low rate of restenosis in patients with Rutherford class 3, 4 or 5 peripheral artery disease, according to the results of a first-in-human study.

An everolimus-eluting bioresorbable scaffold did not affect wound healing compared with angioplasty in patients with chronic limb-threatening ischemia, according to new data from the LIFE-BTK trial.

Most patients with severe chronic limb-threatening ischemia treated with a transcatheter deep venous arterialization system achieved limb salvage at 12 months, according to new data from the PROMISE II trial.

SAN FRANCISCO — Among patients with severe aortic stenosis and small aortic annuli, treatment with transcatheter or surgical aortic valve replacement yielded similar early and late hemodynamic and clinical outcomes in the VIVA trial.

As millennial and older physicians can verify, the path to becoming a physician is long and arduous, filled with years of rigorous education, exams and residency training.

SAN FRANCISCO — A new pooled analysis showed a maintained BP-lowering effect with fewer added medications after treatment with an ultrasound renal denervation system compared with a sham procedure, a speaker reported at TCT 2023.

SAN FRANCISCO — Among patients treated for drug-eluting in-stent restenosis, the revascularization rate at 10 years was high, according to the results of a post hoc analysis of the ISAR-DESIRE 3 trial presented at TCT 2023.